Bluejay Diagnostics Clinical Trial Data
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.